You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

May 27, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Biosimilars need better labeling: Physicians

Eight physician groups urged FDA to ensure that biosimilar product labeling contains all needed data for physicians to make appropriate prescribing decisions for their patients. » Why the concern?

J&J-Achillion partner to develop hep C drugs

Johnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs. » What it means for treatment duration

Continuing Education

MTM essentials for asthma management: Part 2

This month's CE activity is part of the CE series, MTM for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the stepwise approach to the management of pediatric and adult asthma and the pharmacotherapies commonly used in asthma treatment.

To read and print the article with TEST questions, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT30-PYJ23.


Announcement: The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration has been uploaded for your convenience. Current users do not need to register. To review you registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Migraine drug Treximet can now be used in teens

FDA has approved sumatriptan and naproxen sodium (Treximet, Pernix Therapeutics) for the treatment of migraines in pediatric patients. » Details

 

RELATED ARTICLES

FDA issues biosimilar final guidance

Hep C patient sues Blue Cross for denying Harvoni coverage

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA